Abstract:Funding informationSupported by the Shanghai Municipal Key Clinical Specialty (shslczdzk01103). To the editor, We read with interest the autoimmune hepatitis (AIH) case following COVID‐19 vaccination[1] and the comment by Drs. Mungmunpuntipantip and Wiwanitkit.[2] COVID‐19 vaccine could also act as a trigger in the disease course of AIH. We report a case of AIH exacerbation following inactivated whole‐virion SARS‐CoV‐2 vaccine (CoronaVac). The patient is a 57‐year‐old Asian female without medical history. She developed choluria and acholic stools 2 weeks after the first dose of CoronaVac but did not seek medical advice and received the second dose CoronaVac after 3 weeks. Two days later, she developed generalized pruritus and deep scleral and sublingual icterus with markedly elevated total bilirubin (283.8 μmol/L), alanine aminotransferase (974 U/L), aspartate aminotransferase (819 U/L), alkaline phosphatase (212 U/L), and gamma‐glutamyltransferase (238 U/L). She reported no consumption of alcohol or traditional medicine. Viral serologic tests showed negative hepatitis A/B/C/D/E virus, HIV, cytomegalovirus, Epstein‐Barr virus, and herpes simplex virus. Total IgG was slightly elevated (17.44 g/L; normal range, 8.6–17.4 g/L) with positive antinuclear antibodies (1:640, homogeneous pattern), anti–Sjögren syndrome antigen A, anti–major centromere autoantigen B, and weakly positive anti–Sjögren syndrome antigen B. The antimitochondrial, antimitochondrial‐M2, anti–smooth muscle, anti–liver‐kidney microsomal, anti–liver cytosolic, anti–soluble liver antigen, anti‐glycoprotein‐210, and anti‐SP100 antibodies were all negative. Contrasted CT and MRI showed no malignancy and biliary lithiasis or dilation. Liver biopsy revealed established fibrosis (Stage 2) and active hepatitis (Grade 2) with moderate to severe interface necroinflammation, severe lobular lymphocytic/lymphoplasmocytic infiltration, hepatic rosette formation, and a dense lymphoid infiltrate (Figure 1A–F). Both her revised original (20 points) and the simplified (7 points) score for AIH suggested a definite diagnosis of AIH. She had excellent responses to treatment (ursodeoxycholic acid and a tapering course of methylprednisolone overlapped with azathioprine) and no relapse during 5‐month follow‐up (Figure 1G).FIGURE 1: Histological findings and evolution of laboratory tests. At low‐magnification (×100), hematoxylin and eosin staining shows moderate to severe interface hepatitis with a dense lymphoid infiltrate (A), and Masson staining shows the formation of fibrous septa (B). At high magnification (×400) with hematoxylin and eosin stain, the interface necroinflammation consists primarily of lymphocytes with plasma cells (C); the dense periductal lymphocyte infiltrate (D) and the hepatic rosette formation (black circle) were well observed with Masson stain (E). Feathery degeneration of hepatocyte (red arrow) and hepatic cholestasis (black arrow) were also observed (F) (×200 hematoxylin and eosin stain). (G) Trends of liver function tests, total bilirubin, and total IgG levels over time. Dashed lines are the respective lower limit of the normal range of each test. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyltransferase; TB, total bilirubin; UDCA, ursodeoxycholic acidSeveral cases of AIH following COVID‐19 vaccine have been reported,[3] but unlike these cases, the presence of Stage‐2 fibrosis in our case is against the hypothesis of vaccine‐induced AIH onset but suggests vaccine‐induced AIH exacerbation. The vaccination unmasks the undiagnosed AIH and triggers the disease flare. Although CoronaVac vaccination in patients with autoimmune rheumatic diseases is generally safe,[4] our case suggests the need for data in patients with AIH. CONFLICT OF INTEREST Nothing to report. AUTHOR CONTRIBUTIONS Zhujun Cao wrote the draft of the manuscript. Qing Xie and Honglian Gui revised the manuscript. Honglian Gui was involved in the clinical care of the patient. Zhujun Cao, Zike Sheng, Honglian Gui, Haiguang Xin, and Qing Xie were involved in the clinical care of the patient during hospitalization. All authors contributed to and approved the final manuscript.

ERAP-1 and ERAP-2 variants in Liver injury following COVID-19 mRNA Vaccination: A US Multicenter Study

Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines

Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore

Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics

Liver Injury in Patients with COVID-19: A Retrospective Study

COVID-19 vaccine-induced liver injury

Acute liver injury in a COVID-19 infected woman with mild symptoms: A case report

Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases

Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors

Vaccine-Related Autoimmune Hepatitis: Emerging Association with SARS-CoV-2 Vaccination or Coincidence?

Acute hepatitis following mRNA BNT162b2 COVID-19 vaccination

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

RNase2 is a possible trigger of acute-on-chronic inflammation leading to mRNA vaccine-associated cardiac complication

Identification of reduced ERAP2 expression and a novel HLA allele as components of a risk score for susceptibility to liver injury due to amoxicillin-clavulanate

Diagnostic features of autoimmune hepatitis in SARS‑CoV‑2‑vaccinated vs. unvaccinated individuals

Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review

Liver Injury after Antiviral Treatment of Critically Ill Patients with COVID-19: a Single-Centered Retrospective Cohort Study.

Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study

Letter to the Editor: Exacerbation of Autoimmune Hepatitis after COVID-19 Vaccination

Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination